Clinical Trials

88 enrolled

Colonic Neoplasms

NCT07502014 2026-03-30

A Clinical Study of Iparomlimab and Tuvonralimab Combined With Fruquintinib and Heterogeneous Radiotherapy Versus Fruquintinib as Third-Line and Subsequent-Line Treatment for Metastatic Colorectal Cancer

60 enrolled

Phase 3 Not yet recruiting

Colorectal Neoplasms

NCT07483684 2026-03-19

A Clinical Study to Evaluate Injection TQB2102 for the Treatment of Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Progressed After Treatment With Oxaliplatin, Irinotecan and Fluoropyrimidine-Based Drugs

142 enrolled

Phase 4 Not yet recruiting

HER2 IHC3+ Advanced Colorectal Cancer

NCT07446465 2026-03-03

FOLFOX Chemotherapy Combined With Fruquintinib and Serplulimab as First-Line Conversion Therapy for Initially Unresectable pMMR/MSS Colorectal Cancer

42 enrolled

Phase 3 Not yet recruiting

Neoplasm Metastasis, Colorectal Neoplasms

NCT07384377 2026-02-03

JSKN003 Versus Physician Choiced Treatment in Patients With HER2-positive and Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-Fu, and Irinotecan

123 enrolled

HER2-positive Colorectal Cancer

NCT07353268 2026-01-20

Phase Ib/II Study of QL1706 + Fruquintinib + SCRT vs. Standard Third-Line Therapy in Unresectable Liver-Metastatic pMMR/MSS Colorectal Cancer: Safety, Tolerability, and Efficacy.

76 enrolled

Colorectal Neoplasms

NCT07261709 2025-12-03

Trifluridine/Tipiracil Plus Fruquintinib vs. Trifluridine/Tipiracil Plus Bevacizumab in Refractory Metastatic Colorectal Cancer: A Randomized, Controlled, Open-Label, Non-Inferiority Trial

236 enrolled

Colorectal Neoplasms

NCT07229872 2025-11-17

A Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Fruquintinib in the Treatment of Immunodominant pMMR/MSS Metastatic Colorectal Cancer That Has Failed Second-line or Above Treatment

18 enrolled

Colorectal Neoplasms

NCT07170982 2025-09-12

Fruquintinib Combined With Standard Chemotherapy Versus Standard Chemotherapy as First-line Treatment for Advanced pMMR Endometrial Cancer

128 enrolled

Gynecologic

Endometrial Neoplasms

NCT07150403 2025-09-08

Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal Cancer

74 enrolled

Phase NA Not yet recruiting

Colorectal Neoplasms

NCT07124858 2025-08-15

COFRUQ

300 enrolled

Phase NA Not yet recruiting

Colorectal Neoplasms

NCT06985316 2025-05-22

An Exploratory Clinical Study Evaluating the Efficacy and Safety of Tunlametinib Combined With Fruquintinib in the Third-line Treatment of Advanced Colorectal Cancer Patients With RAS Mutations.

34 enrolled

Colorectal Neoplasms

NCT06973421 2025-05-15

Phase II Study of Utidelone Plus Fruquintinib Combination Therapy for Platinum-Resistant Recurrent Ovarian Cancer

35 enrolled

Gynecologic

Platinum Resistant Ovarian Cancer

NCT06871527 2025-03-12

Fruquintinib Combined With PD-1 Inhibitor and FOLFOX as First-Line Treatment For Advanced Gastric Cancer

44 enrolled

Stomach Neoplasms

NCT06706895 2024-11-27

A Single-arm, Single-center Phase II Clinical Study on the Clinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection Combined With Fruquintinib Capsules in the Second-line Treatment of Patients With Advanced Gastric Cancer

21 enrolled

Advanced Gastric Cancer

NCT06484153 2024-07-03

Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Advanced or Metastatic pMMR/MSS Colorectal Carcinoma

25 enrolled

To Evaluate the Efficacy of Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Colorectal Carcinoma

NCT06470178 2024-06-24

A Real-World Study of Neoadjuvant/Conversion Therapy for Colorectal Cancer With Chemotherapy And Anti-Angiogenic Targeted Agents

Not yet recruiting

70 enrolled

Phase 2/3 Not yet recruiting

Colorectal Neoplasms

NCT06443671 2024-06-05

PKUCH-R09

132 enrolled

Rectal Neoplasms

NCT06218888 2024-01-23

A Phase II Clinical Study of the Efficacy and Safety of Tislelizumab Combined With Fruquintinib and Chidamide in the Treatment of Unresectable or Advanced Microsatellite Stabilized (MSS/pMMR) Colorectal Cancer With Liver Metastases

17 enrolled

Colonic Neoplasms

NCT06195670 2024-01-08

Clinical Study of Short-course Radiotherapy Followed by Fruquintinib Plus Sintilimab vs Bevacizumab Plus Capecitabine as First Line Treatment in Advanced mCRC

220 enrolled

Colorectal Neoplasms

NCT06094868 2023-10-23

Clinical Study of Fruquintinib Combined With Sintilimab and XELOX Regimen in the Treatment of Advanced Cancer

45 enrolled

Phase 3 Not yet recruiting

Stomach Neoplasms

NCT05914610 2023-08-25

Envollizumab Combined With Fruquintinib and SOX Versus SOX for Conversion Therapy in Advanced Gastric Cancer

100 enrolled

Stomach Neoplasms

NCT06010212 2023-08-24

Fruquintinib as First Line Treatment in Patients With Recurrent Esophageal Squamous Cell Carcinoma

36 enrolled

Esophageal Squamous Cell Carcinoma

NCT05747716 2023-02-28

SBRT Combined With Fruquintinib Plus PD-1/CTLA-4 Antibody for Third-line Treatment in mCRC

44 enrolled